Literature DB >> 12810724

The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation.

Igal Louria-Hayon1, Tamar Grossman, Ronit Vogt Sionov, Osnat Alsheich, Pier Paolo Pandolfi, Ygal Haupt.   

Abstract

The p53 protein is kept labile under normal conditions. This regulation is governed largely by its major negative regulator, Mdm2. In response to stress however, p53 accumulates and becomes activated. For this to occur, the inhibitory effects of Mdm2 have to be neutralized. Here we investigated the role of the promyelocytic leukemia protein (PML) in the activation of p53 in response to stress. We found that PML is critical for the accumulation of p53 in response to DNA damage under physiological conditions. PML protects p53 from Mdm2-mediated ubiquitination and degradation, and from inhibition of apoptosis. PML neutralizes the inhibitory effects of Mdm2 by prolonging the stress-induced phosphorylation of p53 on serine 20, a site of the checkpoint kinase 2 (Chk2). PML recruits Chk2 and p53 into the PML nuclear bodies and enhances p53/Chk2 interaction. Our results provide a novel mechanistic explanation for the cooperation between PML and p53 in response to DNA damage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810724     DOI: 10.1074/jbc.M301264200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.

Authors:  Alessandra Insinga; Silvia Monestiroli; Simona Ronzoni; Roberta Carbone; Mark Pearson; Giancarlo Pruneri; Giuseppe Viale; Ettore Appella; PierGiuseppe Pelicci; Saverio Minucci
Journal:  EMBO J       Date:  2004-02-19       Impact factor: 11.598

2.  PML: An emerging tumor suppressor and a target with therapeutic potential.

Authors:  Erin L Reineke; Hung-Ying Kao
Journal:  Cancer Ther       Date:  2009-09-01

3.  Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.

Authors:  Sue Haupt; Catherine Mitchell; Vincent Corneille; Jake Shortt; Stephen Fox; Pier Paolo Pandolfi; Mireia Castillo-Martin; Dennis M Bonal; Carlos Cordon-Cardo; Guillermina Lozano; Ygal Haupt
Journal:  Cell Cycle       Date:  2013-05-08       Impact factor: 4.534

Review 4.  The role of PML in the control of apoptotic cell fate: a new key player at ER-mitochondria sites.

Authors:  P Pinton; C Giorgi; P P Pandolfi
Journal:  Cell Death Differ       Date:  2011-04-08       Impact factor: 15.828

Review 5.  PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.

Authors:  Umut Sahin; Hugues de Thé; Valérie Lallemand-Breitenbach
Journal:  Nucleus       Date:  2014       Impact factor: 4.197

6.  Impact of the adenoviral E4 Orf3 protein on the activity and posttranslational modification of p53.

Authors:  Caroline J DeHart; David H Perlman; S J Flint
Journal:  J Virol       Date:  2015-01-07       Impact factor: 5.103

Review 7.  Senescence regulation by the p53 protein family.

Authors:  Yingjuan Qian; Xinbin Chen
Journal:  Methods Mol Biol       Date:  2013

8.  Recruitment of cyclin G2 to promyelocytic leukemia nuclear bodies promotes dephosphorylation of γH2AX following treatment with ionizing radiation.

Authors:  Yoko Naito; Norikazu Yabuta; Jun Sato; Shouichi Ohno; Muneki Sakata; Takashi Kasama; Masahito Ikawa; Hiroshi Nojima
Journal:  Cell Cycle       Date:  2013-05-08       Impact factor: 4.534

9.  PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence.

Authors:  Lisa Ivanschitz; Yuki Takahashi; Florence Jollivet; Olivier Ayrault; Morgane Le Bras; Hugues de Thé
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

10.  Compound In Vivo Inactivation of Pml and p53 Uncovers a Functional Interaction in Angiosarcoma Suppression.

Authors:  Antonella Papa; Carlos Cordon-Cardo; Rosa Bernardi; Pier Paolo Pandolfi
Journal:  Genes Cancer       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.